» Articles » PMID: 36354004

Nidogen-2 is a Novel Endogenous Ligand of LGR4 to Inhibit Vascular Calcification

Overview
Journal Circ Res
Date 2022 Nov 10
PMID 36354004
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vascular calcification is closely related to the all-cause mortality of cardiovascular events. Basement membrane protein nidogen-2 is a key component of the vascular extracellular matrix microenvironment and we recently found it is pivotal for the maintenance of contractile phenotype in vascular smooth muscle cells (VSMCs). However, whether nidogen-2 is involved in VSMCs osteochondrogenic transition and vascular calcification remains unclear.

Methods: VSMCs was treated with high-phosphate to study VSMC calcification in vitro. Three different mice models (5/6 nephrectomy-induced chronic renal failure, cholecalciferol-overload, and periadventitially administered with CaCl) were used to study vascular calcification in vivo. Membrane protein interactome, coimmunoprecipitation, flow cytometric binding assay, surface plasmon resonance, G protein signaling, VSMCs calcium assays were performed to clarify the phenotype and elucidate the molecular mechanisms.

Results: Nidogen-2 protein levels were significantly reduced in calcified VSMCs and aortas from mice in different vascular calcification model. Nidogen-2 deficiency exacerbated high-phosphate-induced VSMC calcification, whereas the addition of purified nidogen-2 protein markedly alleviated VSMC calcification in vitro. mice exhibited aggravated aorta calcification compared to wild-type (WT) mice in response to 5/6 nephrectomy, cholecalciferol-overload, and CaCl administration. Further unbiased coimmunoprecipitation and interactome analysis of purified nidogen-2 and membrane protein in VSMCs revealed that nidogen-2 directly binds to LGR4 (leucine-rich repeat G-protein-coupled receptor 4) with value 26.77 nM. LGR4 deficiency in VSMCs in vitro or in vivo abolished the protective effect of nidogen-2 on vascular calcification. Of interest, nidogen-2 biased activated LGR4-Gαq-PKCα (protein kinase Cα)-AMPKα1 (AMP-activated protein kinase α1) signaling to counteract VSMCs osteogenic transition and mineralization.

Conclusions: Nidogen-2 is a novel endogenous ligand of LGR4 that biased activated Gαq- PKCα-AMPKα1 signaling and inhibited vascular calcification.

Citing Articles

Role of Leucine-Rich Repeat-Containing G-Protein-Coupled Receptors 4-6 (LGR4-6) in the Ovary and Other Female Reproductive Organs: A Literature Review.

Chang Y, Wu K, Wang K, Ding D Cell Transplant. 2025; 34:9636897241303441.

PMID: 39874091 PMC: 11776010. DOI: 10.1177/09636897241303441.


Extracellular matrix in vascular homeostasis and disease.

Zhang L, Zhou J, Kong W Nat Rev Cardiol. 2025; .

PMID: 39743560 DOI: 10.1038/s41569-024-01103-0.


Global proteomics reveals pathways of mesenchymal stem cells altered by Mycobacterium tuberculosis.

Kaur S, Angrish N, Vasudevan M, Khare G Sci Rep. 2024; 14(1):30677.

PMID: 39730375 PMC: 11680934. DOI: 10.1038/s41598-024-75722-5.


Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis.

Kathuria I, Prasad A, Sharma B, Aithabathula R, Ofosu-Boateng M, Gyamfi M Int J Mol Sci. 2024; 25(23).

PMID: 39684493 PMC: 11641205. DOI: 10.3390/ijms252312782.


Dapagliflozin targets SGLT2/SIRT1 signaling to attenuate the osteogenic transdifferentiation of vascular smooth muscle cells.

Li L, Liu H, Chai Q, Wei J, Qin Y, Yang J Cell Mol Life Sci. 2024; 81(1):448.

PMID: 39520538 PMC: 11550308. DOI: 10.1007/s00018-024-05486-8.